On June 30, 2025, MIRA Pharmaceuticals, Inc. announced significant results from animal studies of its drug candidate SKNY-1, achieving about 30% weight loss and reduced nicotine cravings, with a potential market for obesity and smoking treatments exceeding $200 billion.